The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
Open accessAbstract
A rationally designed bi-adjuvant nanovaccine enhances neoantigen immunogenicity and enables combination immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
The history of toll-like receptors - redefining innate immunity
O'Neill, L. A. J., Golenbock, D., & Bowie, A. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3446 · Cited by 1,765
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Endocytosis and exocytosis of nanoparticles in mammalian cells
Park, J. H., & Oh, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s26592 · Cited by 1,176
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
A STING-activating nanovaccine for cancer immunotherapy
Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 900
Self-citationTherapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750
Toward understanding and exploiting tumor heterogeneity
Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3915 · Cited by 746
The perfect mix: recent progress in adjuvant research
Guy, B. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1681 · Cited by 620
A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy
Cho, N.-H., Cheong, T.-C., Min, J. H., Wu, J. H., Lee, S. J., Kim, D., Yang, J.-S., Kim, S., Kim, Y. K., & Seong, S.-Y. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.149 · Cited by 514
Lu, K., He, C., Guo, N., Chan, C., Ni, K., Weichselbaum, R. R., & Lin, W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b06663 · Cited by 505
Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
Strønen, E., Toebes, M., Kelderman, S., van Buuren, M. M., Yang, W., van Rooij, N., Donia, M., Böschen, M.-L., Lund-Johansen, F., Olweus, J., et al. (2016) · Science · doi:10.1126/science.aaf2288 · Cited by 445
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Lynn, G. M., Laga, R., Darrah, P. A., Ishizuka, A. S., Balaci, A. J., Dulcey, A. E., Pechar, M., Pola, R., Gerner, M. Y., Yamamoto, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3371 · Cited by 440
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 439
Engineering Nano‐ and Microparticles to Tune Immunity
Moon, J. J., Huang, B., & Irvine, D. J. (2012) · Advanced Materials · doi:10.1002/adma.201200446 · Cited by 404
Elimination of established tumors with nanodisc-based combination chemoimmunotherapy
Kuai, R., Yuan, W., Son, S., Nam, J., Xu, Y., Fan, Y., Schwendeman, A., & Moon, J. J. (2018) · Science Advances · doi:10.1126/sciadv.aao1736 · Cited by 352
TLR agonists: our best frenemy in cancer immunotherapy
Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0441-y · Cited by 333
Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
Zhu, G., Lynn, G. M., Jacobson, O., Chen, K., Liu, Y., Zhang, H., Ma, Y., Zhang, F., Tian, R., Ni, Q., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02191-y · Cited by 315
Self-citationTrial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20931 · Cited by 244
Engineering Approaches to Immunotherapy
Swartz, M. A., Hirosue, S., & Hubbell, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003763 · Cited by 224
Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy
Fan, Y., Kuai, R., Xu, Y., Ochyl, L. J., Irvine, D. J., & Moon, J. J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03218 · Cited by 220
Pockros, P. J., Guyader, D., Patton, H., Tong, M. J., Wright, T., McHutchison, J. G., & Meng, T.-C. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.025 · Cited by 218
Decker, T., Schneller, F., Sparwasser, T., Tretter, T., Lipford, G. B., Wagner, H., & Peschel, C. (2000) · Blood · doi:10.1182/blood.v95.3.999.003k10_999_1006 · Cited by 210
Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Wang, Q., Wang, X., Ke, L., & Shi, K. (2019) · Theranostics · doi:10.7150/thno.29431 · Cited by 199
Imageable Antigen‐Presenting Gold Nanoparticle Vaccines for Effective Cancer Immunotherapy In Vivo
Lee, I., Kwon, H., An, S., Kim, D., Kim, S., Yu, M. K., Lee, J., Lee, T., Im, S., & Jon, S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203193 · Cited by 194
Ilyinskii, P. O., Roy, C. J., O’Neil, C. P., Browning, E. A., Pittet, L. A., Altreuter, D. H., Alexis, F., Tonti, E., Shi, J., Basto, P. A., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.027 · Cited by 171
RNAi‐Microsponges Form through Self‐Assembly of the Organic and Inorganic Products of Transcription
Shopsowitz, K. E., Roh, Y. H., Deng, Z. J., Morton, S. W., & Hammond, P. T. (2013) · Small · doi:10.1002/smll.201302676 · Cited by 112
Modulated Fragmentation of Proapoptotic Peptide Nanoparticles Regulates Cytotoxicity
Suma, T., Cui, J., Müllner, M., Fu, S., Tran, J., Noi, K. F., Ju, Y., & Caruso, F. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11302 · Cited by 68
Personalized cancer neoantigen vaccines come of age
Chu, Y., Liu, Q., Wei, J., & Liu, B. (2018) · Theranostics · doi:10.7150/thno.24387 · Cited by 64
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
Self-citationCurrent advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Li, Y., Ma, X., Yue, Y., Zhang, K., Cheng, K., Feng, Q., Ma, N., Liang, J., Zhang, T., Zhang, L., et al. (2022) · Advanced Materials · doi:10.1002/adma.202109984 · Cited by 247
Self-citation
Metadata
- Authors
- Ni, Q., Zhang, F., Liu, Y., Wang, Z., Yu, G., Liang, B., Niu, G., Su, T., Zhu, G., Lu, G., Zhang, L., & Chen, X.
- Venue
- Science Advances
- Published
- 2020-03-20
- Volume
- 6
- Issue
- 12
- Pages
- eaaw6071-eaaw6071
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W3010991709
- Cited by
- 281
- References
- 43
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.